Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.323,39
-0,01%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Design Therapeutics Inc (DSGN) Design Therapeutics Inc (DSGN) Notizie

DSGN

Design Therapeutics (DSGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DSGN
DataOraFonteTitoloSimboloCompagnia
08/05/202422:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DSGNDesign Therapeutics Inc
08/05/202422:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
08/05/202422:05GlobeNewswire Inc.Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesNASDAQ:DSGNDesign Therapeutics Inc
07/05/202412:30GlobeNewswire Inc.Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
19/03/202421:01GlobeNewswire Inc.Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
19/03/202412:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:DSGNDesign Therapeutics Inc
12/03/202411:30GlobeNewswire Inc.Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateNASDAQ:DSGNDesign Therapeutics Inc
05/01/202422:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
13/11/202322:05GlobeNewswire Inc.Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024NASDAQ:DSGNDesign Therapeutics Inc
06/09/202323:13Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:DSGNDesign Therapeutics Inc
14/08/202322:05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
14/08/202322:01GlobeNewswire Inc.Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich AtaxiaNASDAQ:DSGNDesign Therapeutics Inc
02/06/202322:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DSGNDesign Therapeutics Inc
01/06/202322:46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DSGNDesign Therapeutics Inc
31/05/202312:30GlobeNewswire Inc.Design Therapeutics to Present at the 2023 Jefferies Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
09/05/202322:05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
24/04/202312:30GlobeNewswire Inc.Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023NASDAQ:DSGNDesign Therapeutics Inc
13/04/202322:41Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:DSGNDesign Therapeutics Inc
03/04/202322:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:DSGNDesign Therapeutics Inc
14/03/202321:27Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:DSGNDesign Therapeutics Inc
14/03/202321:05GlobeNewswire Inc.Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
14/02/202314:16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DSGNDesign Therapeutics Inc
08/02/202312:30GlobeNewswire Inc.Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma ConferenceNASDAQ:DSGNDesign Therapeutics Inc
22/12/202222:26Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:DSGNDesign Therapeutics Inc
08/12/202214:01TipRanksDesign Therapeutics Tanks Even After Positive Clinical DataNASDAQ:DSGNDesign Therapeutics Inc
07/12/202222:01GlobeNewswire Inc.Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressNASDAQ:DSGNDesign Therapeutics Inc
03/11/202221:05GlobeNewswire Inc.Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
17/10/202222:05GlobeNewswire Inc.Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022NASDAQ:DSGNDesign Therapeutics Inc
22/09/202212:30GlobeNewswire Inc.Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine SummitNASDAQ:DSGNDesign Therapeutics Inc
17/08/202203:48TipRanksRBC Capital Sticks to Its Buy Rating for Design Therapeutics (DSGN)NASDAQ:DSGNDesign Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DSGN

La tua Cronologia

USOTC
OGMAS
Otis Gallery (PK)
NYSE
CEG-A.CL
LBNK
HOOKUSDT
Hook Token
BIT
BAY
Bayer
BOV
GGBRQ187
GGBRQ187 Ex:18,7
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network